About Ancora Pharmaceuticals
Ancora Pharmaceuticals is a company based in Milton Keynes (United Kingdom) founded in 2002 was acquired by Corden Pharma in October 2013.. Ancora Pharmaceuticals has raised $800 thousand across 3 funding rounds from investors including HHS and Corden Pharma. Ancora Pharmaceuticals operates in a competitive market with competitors including Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
- Headquarter Milton Keynes, United Kingdom
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Ancora Pharmaceuticals Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$800 K (USD)
in 3 rounds
-
Latest Funding Round
$800 K (USD), Seed
Nov 24, 2009
-
Investors
HHS
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Corden Pharma
(Oct 31, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ancora Pharmaceuticals
Ancora Pharmaceuticals has successfully raised a total of $800K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $800 thousand completed in November 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Seed — $800,000
-
First Round
First Round
(02 Apr 2009)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2009 | Amount | Seed - Ancora Pharmaceuticals | Valuation |
investors |
|
| Apr, 2009 | Amount | Grant - Ancora Pharmaceuticals | Valuation |
investors |
|
| Apr, 2009 | Amount | Grant - Ancora Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ancora Pharmaceuticals
Ancora Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Corden Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
CDMO offering its services for small molecules, peptides, lipids and carbohydrates
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ancora Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ancora Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ancora Pharmaceuticals Comparisons
Competitors of Ancora Pharmaceuticals
Ancora Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Provider of human monoclonal antibodies against infectious diseases
|
|
| domain | founded_year | HQ Location |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Ancora Pharmaceuticals
When was Ancora Pharmaceuticals founded?
Ancora Pharmaceuticals was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Where is Ancora Pharmaceuticals located?
Ancora Pharmaceuticals is headquartered in Milton Keynes, United Kingdom.
Is Ancora Pharmaceuticals a funded company?
Ancora Pharmaceuticals is a funded company, having raised a total of $800K across 3 funding rounds to date. The company's 1st funding round was a Grant of $530.98K, raised on Apr 02, 2009.
What does Ancora Pharmaceuticals do?
Ancora Pharmaceuticals was founded in 2002 and is located in Milton Keynes, United Kingdom. Focus is placed on the biotechnology sector, where vaccines targeting hospital-acquired infections such as those from Staphylococcus, Enterococcus, Candida, and Moraxella are developed. Lead candidates remain in preclinical development. Efforts also extend to vaccines addressing community-acquired infections and potential bioterrorism threats.
Who are the top competitors of Ancora Pharmaceuticals?
Ancora Pharmaceuticals's top competitors include Imvax, Aridis Pharma and Insmed.
Who are Ancora Pharmaceuticals's investors?
Ancora Pharmaceuticals has 2 investors. Key investors include HHS, and Corden Pharma.